Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
This report contains market size and forecasts of Checkpoint Inhibitors for Treating Cancer in global, including the following market information:
Global Checkpoint Inhibitors for Treating Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Checkpoint Inhibitors for Treating Cancer Market Sales, 2017-2022, 2023-2028, (g)
Global top five Checkpoint Inhibitors for Treating Cancer companies in 2021 (%)
The global Checkpoint Inhibitors for Treating Cancer market was valued at 12850 million in 2021 and is projected to reach US$ 59580 million by 2028, at a CAGR of 24.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
PD-1 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Checkpoint Inhibitors for Treating Cancer include Bristol-Myers Squibb(BMS), Merck and Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Checkpoint Inhibitors for Treating Cancer manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Checkpoint Inhibitors for Treating Cancer Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, by Type, 2021 (%)
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Global Checkpoint Inhibitors for Treating Cancer Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, by Application, 2021 (%)
Melanoma Treatment
Bladder Cancer Treatment
Other
Global Checkpoint Inhibitors for Treating Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Checkpoint Inhibitors for Treating Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Checkpoint Inhibitors for Treating Cancer revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Checkpoint Inhibitors for Treating Cancer revenues share in global market, 2021 (%)
Key companies Checkpoint Inhibitors for Treating Cancer sales in global market, 2017-2022 (Estimated), (g)
Key companies Checkpoint Inhibitors for Treating Cancer sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb(BMS)
Merck
Roche